Join to View Full Profile
2151 Berkeley WayBerkeley, CA 94704
Phone+1 415-710-9444
Dr. Giannikopoulos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Molecular Genetic Pathology, 2010 - 2011
Baylor College of MedicineFellowship, Pediatric Pathology, 2009 - 2010
University of California (San Francisco)Residency, Pathology-Anatomic and Clinical, 2007 - 2009- University of California (San Francisco)Residency, Pediatrics, 2006 - 2007
Harvard Medical SchoolClass of 2006
Certifications & Licensure
CO State Medical License 2025 - 2027
CA State Medical License 2008 - 2025
American Board of Pathology Pathology - Anatomic- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Pathology - Pediatric
Publications & Presentations
PubMed
- 8 citationsAssociation of Upper Respiratory Streptococcus pneumoniae Colonization With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Adults.Anna M Parker, Nicole Jackson, Shevya Awasthi, Hanna Kim, Tess Alwan
Clinical Infectious Diseases. 2023-04-03 - Pediatric Sarcomas: The Next Generation of Molecular Studies.Petros Giannikopoulos, David M Parham
Cancers. 2022-05-20 - 5 citationsLuNER: Multiplexed SARS-CoV-2 detection in clinical swab and wastewater samples.Elizabeth C. Stahl, Allan R Gopez, Connor A. Tsuchida, Vinson B. Fan, Erica A. Moehle
Plos One. 2021-11-10
Press Mentions
UC Berkeley COVID-19 Cases Rise Due to Increased Socialization, Delta VariantJuly 21st, 2021- Fact Check: CDC Test Doesn't Conflate COVID-19 Virus with InfluenzaJuly 15th, 2021
‘We Ran Out of Money’: High-Profile Startup Seeking to Connect Patients with Clinical Trials Shuts DownNovember 12th, 2018- Join now to see all
Grant Support
- A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell DiseaseUNIVERSITY OF CALIFORNIA BERKELEY2023–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
